0.9995
price down icon1.04%   -0.0106
after-market Dopo l'orario di chiusura: 1.00 0.00055 +0.06%
loading
Precedente Chiudi:
$1.01
Aprire:
$1
Volume 24 ore:
4,923
Relative Volume:
0.12
Capitalizzazione di mercato:
$3.98M
Reddito:
-
Utile/perdita netta:
$-9.87M
Rapporto P/E:
-0.0253
EPS:
-39.4678
Flusso di cassa netto:
$-8.76M
1 W Prestazione:
-1.04%
1M Prestazione:
-11.55%
6M Prestazione:
-25.41%
1 anno Prestazione:
-89.88%
Intervallo 1D:
Value
$0.9995
$1.00
Intervallo di 1 settimana:
Value
$0.99
$1.04
Portata 52W:
Value
$0.875
$8.40

Revelation Biosciences Inc Stock (REVB) Company Profile

Name
Nome
Revelation Biosciences Inc
Name
Telefono
650-800-3717
Name
Indirizzo
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Name
Dipendente
9
Name
Cinguettio
Name
Prossima data di guadagno
2026-08-06
Name
Ultimi documenti SEC
Name
REVB's Discussions on Twitter

Compare REVB vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
REVB icon
REVB
Revelation Biosciences Inc
0.9995 4.02M 0 -9.87M -8.76M -39.47
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
514.56 132.08B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
793.26 83.15B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
984.04 62.71B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
136.62 54.14B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
203.35 44.51B 742.00K -1.37B -1.07B -7.0731

Revelation Biosciences Inc Borsa (REVB) Ultime notizie

pulisher
Sep 04, 2026

Revelation Biosciences Inc. Warrant (REVBW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com

Sep 04, 2026
pulisher
Sep 04, 2026

Revelation Biosciences Inc (NYSE: REVB) Share Price, REVB Stock News, REVB Share Price & Updates - Kalkine

Sep 04, 2026
pulisher
Sep 04, 2026

Revelation Biosciences Inc. Warrant (REVBW) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com

Sep 04, 2026
pulisher
Sep 02, 2026

Revelation Biosciences (REVB) Climbs 3.13% to $1.02 as Micro-Cap Biotech Tests RangeSymmetrical Triangle - vinanet.vn

Sep 02, 2026
pulisher
Aug 30, 2026

Revelation Biosciences Inc (REVBU) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com

Aug 30, 2026
pulisher
Aug 24, 2026

Revelation (REVB) Technicals: Ends Higher by 0.92% at $1.10 at the Close; Technical View: Traders Can Monitor the $1.04-$1.16 Range in the Current UpdateVanna Flow - vinanet.vn

Aug 24, 2026
pulisher
Aug 20, 2026

Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView

Aug 20, 2026
pulisher
Aug 19, 2026

Enterprise value to EBIT forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView

Aug 19, 2026
pulisher
Aug 19, 2026

Enterprise value to revenue forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView

Aug 19, 2026
pulisher
Aug 19, 2026

Revelation Biosciences Grants Performance-Based Restricted Stock to CEO and CFO - Minichart

Aug 19, 2026
pulisher
Aug 19, 2026

Form 8K Revelation Biosciences Inc For: 19 August By Investing.com - Investing.com Nigeria

Aug 19, 2026
pulisher
Aug 19, 2026

Revelation Biosciences grants restricted stock awards to CEO and CFO - Investing.com

Aug 19, 2026
pulisher
Aug 19, 2026

Revelation Biosciences Grants Performance-Based Executive Stock Awards - TipRanks

Aug 19, 2026
pulisher
Aug 19, 2026

Revelation Biosciences grants restricted shares to James Rolke and Chester S. Zygmont III - TradingView

Aug 19, 2026
pulisher
Aug 19, 2026

Revelation Biosciences (REVB) ties CEO, CFO pay to $30–120M cap tests - Stock Titan

Aug 19, 2026
pulisher
Aug 19, 2026

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study - biospace.com

Aug 19, 2026
pulisher
Aug 19, 2026

Revelation Biosciences selects CRO for phase 2/3 AKI study By Investing.com - Investing.com Canada

Aug 19, 2026
pulisher
Aug 19, 2026

Revelation Biosciences selects CRO for phase 2/3 AKI study - Investing.com

Aug 19, 2026
pulisher
Aug 19, 2026

Revelation Biosciences Selects Avance Clinical As Cro For Phase 2/3 Titan Study - TradingView

Aug 19, 2026
pulisher
Aug 18, 2026

Revelation Biosciences (REVB) CFO gifts 416K shares - Stock Titan

Aug 18, 2026
pulisher
Aug 18, 2026

Revelation Biosciences (NASDAQ: REVB) grants director 32K restricted shares - Stock Titan

Aug 18, 2026
pulisher
Aug 18, 2026

Revelation Biosciences (NASDAQ: REVB) details insider trade - Stock Titan

Aug 18, 2026
pulisher
Aug 18, 2026

Revelation Biosciences (REVB) insider logs stock trade in company shares - Stock Titan

Aug 18, 2026
pulisher
Aug 14, 2026

Armistice Capital (REVB) discloses 4.99% Revelation Biosciences stake via Master Fund - Stock Titan

Aug 14, 2026
pulisher
Aug 12, 2026

REVB Q2 2026 Earnings: Loss per Share Misses Consensus as Pre-Revenue Pipeline AdvancesCFO Commentary Report - Vinanet

Aug 12, 2026
pulisher
Aug 08, 2026

Price to book forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView

Aug 08, 2026
pulisher
Aug 08, 2026

Price to sales forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView

Aug 08, 2026
pulisher
Aug 07, 2026

Revelation Biosciences, Inc. (REVBW) Stock Price, News, Quote & History - Yahoo! Finance Canada

Aug 07, 2026
pulisher
Aug 06, 2026

Revelation Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Revelation Biosciences reports $3.3M net loss for Q2 2026, $11.5M cash on hand - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

BRIEF-Revelation Biosciences Inc Q2 EPS USD -0.87 - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

REVELATION BIOSCIENCES 2Q 2026: Net loss $(3.32M), EPS $(0.87) — 10-Q Summary - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Revelation Biosciences (Nasdaq: REVB) posts Q2 loss and flags cash risk - Stock Titan

Aug 06, 2026
pulisher
Aug 06, 2026

REVB Q2'26 Earnings: EPS estimate is (0.83) USD - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

REVB: Q2 net loss widened to $3.3M; Gemini targets a $94B market with cash runway through Q1 2027 - TradingView

Aug 06, 2026
pulisher
Aug 04, 2026

Revelation Biosciences Inc expected to post a loss of 83 cents a shareEarnings Preview - TradingView

Aug 04, 2026
pulisher
Aug 03, 2026

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury - New Castle News

Aug 03, 2026
pulisher
Jul 31, 2026

Revelation Biosciences (NASDAQ:REVB) secures FDA agreement setting single-study path for kidney drug Gemini - Kalkine

Jul 31, 2026
pulisher
Jul 27, 2026

Revelation Biosciences Inc (REVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Revelation Biosciences Inc (REVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Revelation Biosciences Inc (REVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Revelation Biosciences Inc (REVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

REVB|Revelation Biosciences Inc|Price:1.050|Chg%:-0.010 - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Revelation Biosciences Inc (REVB) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

TradingKey - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

Revelation Biosciences Inc (REVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Revelation Biosciences Inc (REVB) Institutional Confidence - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Revelation Biosciences Inc (REVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

REVB|Revelation Biosciences Inc|Price:1.060|Chg%:-0.030 - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

REVB Q1 2026 Earnings: Significant EPS Miss with No Revenue ReportedOne-Time Gain Impact - vinanet.vn

Jul 26, 2026

Revelation Biosciences Inc Azioni (REVB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$58.75
price down icon 3.04%
$127.28
price down icon 1.18%
$40.94
price down icon 2.08%
$247.51
price down icon 4.07%
ONC ONC
$341.80
price down icon 2.62%
$203.35
price down icon 2.08%
Capitalizzazione:     |  Volume (24 ore):